Market Overview

UPDATE: Northland Downgrades ResMed

Related RMD
ResMed Acquires Maribo Medico; Financial Terms Not Disclosed
Leader In The 'Growing' Sleep-Disordered Breathing Market Might Be Worth An Investment

In a note released Tuesday morning, Northland Securities downgraded ResMed (NYSE: RMD) from Market perform to Underperform and maintained its $40 price target.

In the note, Northland analyst cited "numerous forces" in the CPAP space that will squeeze margins and the top-line overtime. Furthermore, the analysts noted that ResMed's model is "highly sensitive" to operating margins and believe that consensus estimates are "unrealistic."

Shares of ResMed are down a little over one percent at $49.44 in Tuesday's trading.

Latest Ratings for RMD

Sep 2015Goldman SachsUpgradesNeutralBuy
Jul 2015Morgan StanleyUpgradesEqual-weightOverweight
Jun 2015BarclaysInitiates Coverage onEqual-weight

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Northland SecuritiesDowngrades Price Target Analyst Ratings


Related Articles (RMD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters